readthroughSign in
Nov 10, 2026Quarterly update6 fact check notes

Cumberland sets ifetroban DMD heart-disease NDA plan after Apotex deal closes

The company reported Q3 2026 results, a $100 million strategic transaction close, and mixed next steps for ifetroban in two rare-disease programs.

Cumberland Pharmaceuticals said on November 10, 2026 that it plans to submit a New Drug Application to the FDA for ifetroban as a treatment for the cardiomyopathy associated with Duchenne muscular dystrophy.

The filing will also include long-term open-label extension data, preclinical findings published in the Journal of the American Heart Association, manufacturing information, and a safety database covering more than 1,400 subjects across roughly 30 clinical studies.1 Across up to 36 months of treatment in the Phase 2 trial and its extension, the company reported a favorable safety profile with no treatment-related serious adverse events or new safety signals.1

Separately, Cumberland reported top-line results from its Phase 2a ASSIST-SSc trial in systemic sclerosis. Cumberland plans to submit the clinical study report to the FDA and complete correlative biomarker and cardiac imaging work from patients in the open-label extension, which will inform its decision on further development in this indication.1

The quarter was the first following the July 1, 2026 close of Cumberland's Strategic Transaction with Apotex Health, under which Cumberland's commercial brands and organization were integrated into Apotex's U.S. branded business in exchange for $100 million in proceeds that strengthened the balance sheet and let Cumberland focus resources on its clinical pipeline.1

Fact check notes

  • Sentence removedThe decision follows a pre-NDA meeting with the FDA in the fall of 2026, and the FDA granted Cumberland's request for a rolling review, which allows completed sections of the application to be submitted before the entire filing is complete.copied source wording
  • Sentence removedThe submission will draw on Phase 2 FIGHT DMD trial data showing a statistically significant 5.4 percentage point improvement in left ventricular ejection fraction (p=0.002) in the high-dose group versus a control group of placebo patients combined with propensity score-matched natural history patients.copied source wording
  • Sentence removedIfetroban holds Orphan Drug, Rare Pediatric Disease and Fast Track designations, and the FDA has conditionally accepted DYSCORBAN as the product's proprietary name.copied source wording
  • Sentence removedIfetroban was generally well tolerated, with a safety profile consistent with prior experience, and no serious adverse event during the 12-month treatment period was judged related to study drug.copied source wording
  • Sentence removedNet income for the quarter was $77.8 million, reflecting the gain on divestiture tied to the transaction.a figure with no citation
  • Sentence removedAt September 30, 2026, the company held $80.6 million in cash and cash equivalents against total assets of about $114 million, with total liabilities of $41,604,127 and total shareholders' equity of $72,505,965.a figure with no citation

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.